El-Banani, H., Bernard, M., Baetz, D., et al. (2000) Changes in Intracellular Sodium and pH during Ischemia-Reperfusion Are Attenuated by Trimetazidine. Comparison between Low- and Zero-Flow Ischemia. Cardiovascular Research, 47, 688-696.
https://doi.org/10.1016/S0008-6363(00)00136-X

has been cited by the following article:

• TITLE: Role of Trimetazidine in Coronary Artery Bypass Graft Surgery

  AUTHORS: Gerez Fernandes Martins, Gerez Martins

  KEYWORDS: Ischemia-Reperfusion Injury, Oxidative Stress, Inflammation, Trimetazidine, Coronary Artery Bypass Graft

  JOURNAL NAME: World Journal of Cardiovascular Surgery, Vol.7 No.7, July 26, 2017

  ABSTRACT: Trimetazidine is a drug that has been used to reduce the damage of reperfusion injury, which is a mechanism of oxidative aggression that occurs in coronary syndromes, angioplasty procedures, as well as in cardiovascular surgeries. Seeking to improve myocardial protection during procedures that involve reperfusion, attention was recently turned to research on cytoprotective drugs which act on segments of cellular metabolism, used in isolation or combined to reduce or prevent damage to the cardiac cell. The aim of this review is to objectively evaluate the effects of the drug trimetazidine (TMZ) on ischemia-reperfusion injury in coronary artery bypass graft surgery by reviewing all known studies from recent years.